Starton Opens Second Site for Phase 1b STAR-LLD Myeloma Trial with Progress Update

A clinical-stage biotech firm, Starton Therapeutics, has announced the initiation of its Regional Medical Oncology Center (RMOC) in Wilson, NC, for the STAR-LLD Phase 1b clinical trial. The trial, which is evaluating a continuous subcutaneous delivery of low-dose lenalidomide combined with dexamethasone and bortezomib, is progressing faster than expected. Initially set to complete patient enrollment in Q3/24, it is now anticipated to reach full enrollment by Q1/24.
Dr. Keith Lerro, a medical oncologist and hematologist at RMOC, expressed enthusiasm about the potential benefits of the STAR-LLD treatment for multiple myeloma patients. Starton has reported preliminary findings indicating a favorable safety profile for STAR-LLD, with no observed hematologic toxicities beyond Grade 1 after three treatment cycles. Moreover, the treatment has shown no drug-related non-hematologic toxicities beyond Grade 1, with only one adverse event reported over six cycles.
The CEO of Starton, Pedro Lichtinger, highlighted the positive impact of the clinical study's accelerated progress and the promising patient outcomes. He emphasized the company's mission to extend patients' lives while improving their quality of life and creating value for stakeholders. The clinical data align with preclinical findings, showing no significant hematologic toxicity or drug-related adverse events.
Dr. Mohamad Hussein, a leading expert in multiple myeloma treatment and a Starton board member, praised the innovative lenalidomide administration method, noting its potential to enhance safety and tolerability for patients. The absence of common side effects associated with oral lenalidomide (Revlimid®) in the STAR-LLD treatment suggests a superior tolerability profile. This could lead to a broader patient population benefiting from the treatment and an improved quality of life.
Starton Therapeutics is dedicated to transforming cancer care through its proprietary continuous delivery technology, aiming to increase the efficacy of approved drugs and make them more tolerable. 

How to obtain the latest research advancements in the field of biopharmaceuticals?

In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!